Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Department of Anesthesiology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Korean J Anesthesiol. 2019 Aug;72(4):344-350. doi: 10.4097/kja.d.18.00355. Epub 2019 May 17.
Enhanced recovery protocols (ERP) provide optimal perioperative care for surgical patients. Postoperative nausea and vomiting (PONV) is common after colorectal surgery (CRS). We aim to compare the efficacy of aprepitant to a cost-effective alternative, perphenazine, as components of triple antiemetic prophylaxis in ERP patients.
Patients who underwent ERP CRS at a single institution from July 2015 to July 2017 were evaluated retrospectively. Only subjects who received aprepitant (Group 1) or perphenazine (Group 2) preoperatively for PONV prophylaxis were included. Patient characteristics, simplified Apfel PONV scores, perioperative medications, and PONV incidence were compared between the groups. PONV was defined as the need for rescue antiemetics on postoperative days (POD) 0-5.
Five hundred ninety-seven patients underwent CRS of which 498 met the inclusion criteria. Two hundred thirty-one (46.4%) received aprepitant and 267 (53.6%) received perphenazine. The incidence of early PONV (POD 0-1) was comparable between the two groups: 44.2% in Group 1 and 44.6% in Group 2 (P = 0.926). Late PONV (POD 2-5) occurred less often in Group 1 than Group 2, respectively (35.9% vs. 45.7%, P = 0.027). After matching the groups for preoperative, procedural, and anesthesia characteristics (164 pairs), no difference in early or late PONV could be demonstrated between the groups.
The incidence of PONV remains high despite most patients receiving three prophylactic antiemetic medications. Perphenazine can be considered a cost-effective alternative to oral aprepitant for prophylaxis of PONV in patients undergoing CRS within an ERP.
强化康复方案(ERP)为外科患者提供最佳围手术期护理。结直肠手术后(CRS)后常发生术后恶心和呕吐(PONV)。我们旨在比较阿瑞匹坦与一种具有成本效益的替代药物奋乃静作为 ERP 患者三联止吐预防方案的组成部分的疗效。
回顾性评估了 2015 年 7 月至 2017 年 7 月在一家机构接受 ERP-CRS 的患者。仅纳入接受阿瑞匹坦(第 1 组)或奋乃静(第 2 组)术前预防 PONV 的患者。比较两组患者的特征、简化的阿普加 PONV 评分、围手术期用药和 PONV 发生率。PONV 定义为术后第 0-5 天需要解救性止吐药。
597 例患者接受 CRS,其中 498 例符合纳入标准。231 例(46.4%)接受阿瑞匹坦,267 例(53.6%)接受奋乃静。两组早期 PONV(术后第 0-1 天)发生率相似:第 1 组 44.2%,第 2 组 44.6%(P = 0.926)。第 1 组迟发性 PONV(术后第 2-5 天)发生率低于第 2 组,分别为 35.9%和 45.7%(P = 0.027)。对两组的术前、手术和麻醉特征进行匹配(164 对)后,两组间的早期或迟发性 PONV 差异无统计学意义。
尽管大多数患者接受了三种预防性止吐药物,但 PONV 的发生率仍然很高。在 ERP 中接受 CRS 的患者中,奋乃静可被认为是口服阿瑞匹坦预防 PONV 的一种具有成本效益的替代药物。